美国与英格兰前列腺癌男性治疗比较:一项基于国际人群的研究
该研究利用美国SEER数据库(109,697例)和英格兰NPCA数据库(74,393例)纳入2014年4月1日至2016年12月31日新诊断的非转移性前列腺癌患者,比较两国初始治疗差异。美国各预后分组接受根治性局部治疗的比例均高于英格兰,作者提出美国低危(CPG1)可能过度治疗、英格兰临床显著疾病(CPG3-5)可能治疗不足的担忧。
要点
- 美国各CPG分组根治性局部治疗率均高于英格兰。
- CPG1组美国38.1% vs 英格兰14.3%,aRR 2.57(95%CI 2.47-2.68)。
- CPG3-5组美国治疗率亦高于英格兰,aRR 1.06-1.12。
核心结论
- 美国非转移性前列腺癌患者的根治性局部治疗率高于英格兰,作者提出美国低危(CPG1)可能过度治疗、英格兰临床显著疾病(CPG3-5)可能治疗不足的担忧。
研究设计与样本
- 基于人群的国际比较研究,使用美国SEER数据库(109,697例)和英格兰NPCA数据库(74,393例),纳入2014年4月1日至2016年12月31日新诊断的非转移性前列腺癌男性,采用多因素回归估计调整风险比(aRR),以CPG五分类作为交互项。
主要发现
- CPG1组接受根治性局部治疗比例美国38.1% vs 英格兰14.3%,aRR 2.57(95%CI 2.47-2.68)。
- CPG2组美国68.6% vs 英格兰52.6%,aRR 1.27(95%CI 1.25-1.29)。
- CPG3组美国76.7% vs 英格兰67.1%,aRR 1.12(95%CI 1.10-1.13)。
- CPG4组美国82.6% vs 英格兰72.4%,aRR 1.09(95%CI 1.08-1.10)。
- CPG5组美国78.2% vs 英格兰71.7%,aRR 1.06(95%CI 1.04-1.07)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The treatment of prostate cancer varies between the United States (US) and England, however this has not been well characterised using recent data. We therefore investigated the extent of the differences between US and English patients with respect to initial treatment. METHODS: We used the Surveillance, Epidemiology, and End Results (SEER) database to identify men diagnosed with prostate cancer in the US and the treatments they received. We also used the National Prostate Cancer Audit (NPCA) database for the same purposes among men diagnosed with prostate cancer in England. Next, we used multivariable regression to estimate the adjusted risk ratio (aRR) of receiving radical local treatment for men with non-metastatic prostate cancer according to the country of diagnosis (US vs. England). The five-tiered Cambridge Prognostic Group (CPG) classification was included as an interaction term. RESULTS: We identified 109,697 patients from the SEER database, and 74,393 patients from the NPCA database, who were newly diagnosed with non-metastatic prostate cancer between April 1st 2014 and December 31st 2016 with sufficient information for risk stratification according to the CPG classification. Men in the US were more likely to receive radical local treatment across all prognostic groups compared to men in England (% radical treatment US vs. England, CPG1: 38.1% vs. 14.3% - aRR 2.57, 95% CI 2.47-2.68; CPG2: 68.6% vs. 52.6% - aRR 1.27, 95% CI 1.25-1.29; CPG3: 76.7% vs. 67.1% - aRR 1.12, 95% CI 1.10-1.13; CPG4: 82.6% vs. 72.4% - aRR 1.09, 95% CI 1.08-1.10; CPG5: 78.2% vs. 71.7% - aRR 1.06, 95% CI 1.04-1.07) CONCLUSIONS: Treatment rates were higher in the US compared to England raising potential over-treatment concerns for low-risk disease (CPG1) in the US and under-treatment of clinically significant disease (CPG3-5) in England.
引用
- Parry MG, Nossiter J, Morris M, et al. Comparison of the treatment of men with prostate cancer between the US and England: an international population-based study. Prostate Cancer Prostatic Dis. 2022. PMID: 35001083. doi:10.1038/s41391-021-00482-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。